Lynparza breast cancer Clinical Experience Investigation
Study identifier:D0819C00005
ClinicalTrials.gov identifier:NCT03590938
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Lynparza Tablets 100mg, 150mg CEI, Investigation on development of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy
Medical condition
Breast Cancer
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
111
Study type
Observational
Age
N/A
Date
Study Start Date: 14 Aug 2018
Primary Completion Date: 24 Mar 2022
Study Completion Date: 24 Mar 2022
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Apr 2022 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Toshimitsu Tokimoto
AstraZeneca KK
